CD19-STAR-T Cells is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase I drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD19-STAR-T Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD19-STAR-T Cells overview

Gene therapy is under development for the treatment of refractory and relapsed of B-cell malignancies including acute lymphocytic leukemia and B-cell non-Hodgkin lymphoma. It acts by targeting cells expressing CD-19. The therapeutic candidate consists of autologous T cells genetically engineered with lentiviral vector encoding synthetic T cell antigen receptor (STAR). The drug candidate is administered by intravenous route as infusion.

Bristar Immunotech Biotechnology overview

Bristar Immunotech Biotechnology (Bristar Immunotech) is a biotechnology company focused on development and commercialization of cellular immunotherapy products for various diseases represented by TCR-T. Huaxia Yingtai is headquartered in Beijing, China.

For a complete picture of CD19-STAR-T Cells’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.